Filed with NSE · · 3 pages · English
Glenmark Pharmaceuticals Limited has launched TEVIMBRA® in India, an innovative immuno-oncology treatment for non-small cell lung cancer and esophageal squamous cell carcinoma. This launch follows approval from the Central Drugs Standard Control Organization and marks Glenmark's entry into the immune-oncology sector in India. TEVIMBRA is designed to enhance T-cell function while minimizing immune suppression and has shown efficacy in multiple pivotal studies. The company aims to improve access to advanced cancer therapies amid a rising cancer burden in the country.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 24, 2025, titled "Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma".
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals